Cargando…

Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE‐LY Trial

BACKGROUND: Cardiac biomarkers and left ventricular hypertrophy (LVH) are related to the risk of stroke and death in patients with atrial fibrillation. We investigated the interrelationship between LVH and cardiac biomarkers and their independent associations with outcomes. METHODS AND RESULTS: Plas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hijazi, Ziad, Verdecchia, Paolo, Oldgren, Jonas, Andersson, Ulrika, Reboldi, Gianpaolo, Di Pasquale, Giuseppe, Mazzotta, Giovanni, Angeli, Fabio, Eikelboom, John W., Ezekowitz, Michael D., Connolly, Stuart J., Yusuf, Salim, Wallentin, Lars
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497355/ https://www.ncbi.nlm.nih.gov/pubmed/30651032 http://dx.doi.org/10.1161/JAHA.118.010107

Ejemplares similares

Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study
por: Verdecchia, Paolo, et al.
Publicado: (2018)

Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study
por: McAlister, Finlay A., et al.
Publicado: (2020)

Evaluation of the Age, Biomarkers, and Clinical History–Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials
por: Hijazi, Ziad, et al.
Publicado: (2020)

Electrocardiography for diagnosis of left ventricular hypertrophy in hypertensive patients with atrial fibrillation
por: Angeli, Fabio, et al.
Publicado: (2019)

Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation
por: Hijazi, Ziad, et al.
Publicado: (2020)

Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation
por: Pol, Tymon, et al.
Publicado: (2021)

A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score
por: Hijazi, Ziad, et al.
Publicado: (2018)

The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction
por: Verdecchia, Paolo, et al.
Publicado: (2008)

Detrimental Impact of Chronic Obstructive Pulmonary Disease in Atrial Fibrillation: New Insights from Umbria Atrial Fibrillation Registry
por: Angeli, Fabio, et al.
Publicado: (2019)

Comparative assessment of angiotensin receptor blockers in different clinical settings
por: Verdecchia, Paolo, et al.
Publicado: (2009)

Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
por: Angeli, Fabio, et al.
Publicado: (2021)

Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation
por: Benz, Alexander P, et al.
Publicado: (2023)

Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation
por: Hijazi, Ziad, et al.
Publicado: (2022)

Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials
por: Reboldi, Gianpaolo, et al.
Publicado: (2009)

Hypertension and myocarditis following COVID-19 vaccination. Two sides of the coin?()
por: Angeli, Fabio, et al.
Publicado: (2023)

Efficacy and safety of dabigatran versus warfarin from the RE-LY trial
por: Avezum, Alvaro, et al.
Publicado: (2018)

Diuretic Treatment of Hypertension
por: Grossman, Ehud, et al.
Publicado: (2011)

Edoxaban in the Evolving Scenario of Non Vitamin K Antagonist Oral Anticoagulants Imputed Placebo Analysis and Multiple Treatment Comparisons
por: Verdecchia, Paolo, et al.
Publicado: (2014)

SARS-CoV-2 vaccines: Lights and shadows
por: Angeli, Fabio, et al.
Publicado: (2021)

Use of Oral Anticoagulants in Patients with Atrial Fibrillation: Preliminary Data from the Italian Atrial Fibrillation (ITALY-AF) Registry
por: Angeli, Fabio, et al.
Publicado: (2023)

Type 2 Valvular Heart Disease Affects Decision Making for Anticoagulation in Patients with Atrial Fibrillation: The UMBRIA-Fibrillazione Atriale Prospective Study
por: Vedovati, Maria Cristina, et al.
Publicado: (2019)

Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time
por: Hijazi, Ziad, et al.
Publicado: (2017)

The revolution of the anti-diabetic drugs in cardiology
por: Verdecchia, Paolo, et al.
Publicado: (2020)

Blood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis
por: Angeli, Fabio, et al.
Publicado: (2022)

COVID-19, vaccines and deficiency of ACE(2) and other angiotensinases. Closing the loop on the "Spike effect"
por: Angeli, Fabio, et al.
Publicado: (2022)

Risk of ischemic stroke and utility of CHA(2)DS(2)‐VASc score in women and men with atrial fibrillation
por: Tomasdottir, Maria, et al.
Publicado: (2019)

Echocardiography in Low‐Risk Hypertensive Patients
por: Mancusi, Costantino, et al.
Publicado: (2019)

The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: One year later
por: Angeli, Fabio, et al.
Publicado: (2021)

The spike effect of acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 vaccines on blood pressure()
por: Angeli, Fabio, et al.
Publicado: (2023)

Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas
por: Pol, Tymon, et al.
Publicado: (2021)

Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial
por: Åsberg, Signild, et al.
Publicado: (2017)

Early Versus Delayed Non–Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study
por: Oldgren, Jonas, et al.
Publicado: (2022)

Impact of Chamber Dilatation on the Prognostic Value of Left Ventricular Geometry in Hypertension
por: Verdecchia, Paolo, et al.
Publicado: (2017)

Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial
por: Sandhu, Roopinder K, et al.
Publicado: (2018)

The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation
por: Hijazi, Ziad, et al.
Publicado: (2016)

Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)
por: Connolly, Stuart J., et al.
Publicado: (2013)

Serum Neurofilament Light Chain in Patients With Atrial Fibrillation
por: Sjölin, Karl, et al.
Publicado: (2022)

Interpretation of Ambulatory Blood Pressure Monitoring for Risk Stratification in Hypertensive Patients: The ‘Ambulatory Does Prediction Valid (ADPV)’ Approach
por: Angeli, Fabio, et al.
Publicado: (2023)

Electrocardiographic features of patients with COVID-19 pneumonia
por: Angeli, Fabio, et al.
Publicado: (2020)

Electrocardiographic features of patients with COVID-19: One year of unexpected manifestations
por: Angeli, Fabio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ie27ktjtb0mri66npd6l48943b